Jump to content

Lonza Group: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
m (GR) Duplicate: File:Lonza.svgFile:Lonza Logo.svg Exact or scaled-down duplicate: c::File:Lonza Logo.svg
 
(27 intermediate revisions by 21 users not shown)
Line 1: Line 1:
{{Short description|Swiss chemical and biotech company}}
{{Short description|Swiss pharmaceutical and biotech company}}
{{Infobox company
{{Infobox company
| name = Lonza Group AG
| name = Lonza Group AG
| logo = Lonza.svg
| logo = Lonza Logo.svg
| logo_size = 200px
| logo_size = 200px
| image = Basel - 2017 - Lonza Hochhaus1.jpg
| image_size = 250px
| image_caption = Lonza Tower in [[Basel]], Switzerland
| type = [[Aktiengesellschaft]]
| type = [[Aktiengesellschaft]]
| traded_as = {{SWX|LONN}}, {{sgx|O6Z}}
| traded_as = {{unbulleted list| {{SWX|LONN}} | {{SGX|O6Z}} | [[Swiss Market Index|SMI]] component}}
| foundation = 1897
| foundation = {{start date and age|1897}}
| location = [[Basel]], [[Switzerland]]
| location = [[Basel]], Switzerland
| key_people = {{unbulleted list|Jean-Marc Huët ([[chairman]])|[[Wolfgang Wienand]] ([[Chief Executive Officer|CEO]])}}
| key_people = Pierre-Alain Ruffieux <small>([[CEO]])</small>
| industry = [[Chemical industry|Chemicals]]<br/>[[biotechnology]]
| industry = {{unbulleted list|[[Pharmaceutical industry|Pharmaceuticals]]|[[biotechnology]]}}
| products = [[Biopharmaceutical]]s
| products = [[Biopharmaceutical]]s, [[organic chemistry|organic]] and [[fine chemicals]], [[chemical synthesis]] equipment, custom manufacturing of chemicals and related products
| revenue = [[Swiss franc|CHF]] 5.9 billion <small>(2019)</small><ref name="AR2018">{{cite web |url=https://lonza.com/-/media/Lonza/Lonzacom/investor-relations/Financial-Reports/2019_Full_Year_Results.pdf |format=PDF |title=Annual Results 2019 }}</ref>
| revenue = {{increase}} {{CHF|6.72 billion|link=yes|ISO=yes}} (2023)<ref name="AR2023">{{cite web |url=https://www.lonza.com/annualreport/2023/documents/Lonza_2023_Annual_Report.pdf |format=PDF |title=Annual Report 2023 |access-date=10 June 2024 |publisher=Lonza Group }}</ref>
| operating_income = CHF 842 million <small>(2018)</small><ref name="AR2018" />
| operating_income = {{decrease}} CHF 880 million (2023)<ref name="AR2023" />
| net_income = {{decrease}} CHF 655 million (2023)<ref name="AR2023" />
| net_income =
| assets = CHF 13.921 billion <small>(end 2018)</small><ref name="AR2018" />
| assets = {{nowrap|{{decrease}} CHF 16.8 billion (2023)<ref name="AR2023" />}}
| equity = CHF 6.290 billion <small>(end 2018)</small><ref name="AR2018" />
| equity = {{decrease}} CHF 9.51 billion (2023)<ref name="AR2023" />
| num_employees = 15,375 {{small|(2018)}}
| num_employees = 18,000 (2023)<ref name="AR2023" />
| owner =
| owner =[[BlackRock|Blackrock]](9.67%)<ref>https://www.lonza.com/investor-relations/shareholders-and-stock-information</ref><ref name="simplywall.st">https://simplywall.st/stocks/ch/pharmaceuticals-biotech/vtx-lonn/lonza-group-shares/news/what-kind-of-shareholders-own-lonza-group-ltd-vtxlonn/</ref>
| homepage = {{url|lonza.com}}

[[Artisan Partners]](3.2%)<ref>https://annualreport.lonza.com/2019/company/investor-information.html</ref>
<ref name="simplywall.st">https://simplywall.st/stocks/ch/pharmaceuticals-biotech/vtx-lonn/lonza-group-shares/news/what-kind-of-shareholders-own-lonza-group-ltd-vtxlonn/</ref>

[[The Vanguard Group]](3.0%)<ref name="simplywall.st">https://simplywall.st/stocks/ch/pharmaceuticals-biotech/vtx-lonn/lonza-group-shares/news/what-kind-of-shareholders-own-lonza-group-ltd-vtxlonn/</ref>
| homepage = [https://www.lonza.com www.lonza.com]
}}
}}
'''Lonza Group''' is a [[Switzerland|Swiss]] multinational [[chemical engineering|chemical]]s and [[biotechnology]] company, headquartered in [[Basel]], with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the [[pharmaceutical]] and [[biologic medical product|biologic]] industries, including [[organic chemistry|organic]], [[fine chemicals|fine]] and performance chemicals, custom manufacturing of [[biopharmaceutical]]s, [[chemical synthesis]] capabilities, detection systems and services for the [[bioscience]] sector. <!-- Looking to use the Company article structure proposed at https://en.wikipedia.org/wiki/Wikipedia_talk:WikiProject_Companies/Guidelines#Suggested_Structure in 2011. -->
'''Lonza Group AG''' is a [[Switzerland|Swiss]] multinational manufacturing company for the [[Pharmaceutical industry|pharmaceutical]], [[biotechnology]] and [[Human nutrition|nutrition]] sectors, headquartered in [[Basel]], with major facilities in [[Europe]], North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the [[pharmaceutical]] and [[biologic medical product|biologic]] industries, including custom manufacturing of [[biopharmaceutical]]s and detection systems and services for the [[bioscience]] sector.


==History==
==History==
Lonza was founded in 1897 in the small Swiss town of [[Gampel]], situated in the canton of [[Valais]], taking its name from the nearby [[Lötschental|river]]. In the course of the 20th century Lonza evolved from hydroelectricity and C2 chemistry, through nitrogen chemistry to petrochemistry before moving into fine chemistry and biochemistry.<ref name="WaltE">{{cite journal |last1=Eschenmooser |first1=Walter |title=100 Years of Progress with LONZA |journal=Chimia |date=June 1997 |volume=51 |issue=6 |pages=259–269 |url=https://www.ingentaconnect.com/content/scs/chimia/1997/00000051/00000006/art00002?crawler=true&mimetype=application/pdf |access-date=8 October 2020}}</ref>
Lonza was founded in 1897 in the small Swiss town of [[Gampel]], situated in the canton of [[Valais]], taking its name from the nearby [[Lötschental|river]]. In the course of the 20th century Lonza evolved from hydroelectricity and C2 chemistry, through nitrogen chemistry to petrochemistry before moving into fine chemistry and biochemistry.<ref name="WaltE">{{cite journal |last1=Eschenmooser |first1=Walter |title=100 Years of Progress with LONZA |journal=CHIMIA |date=June 1997 |volume=51 |issue=6 |pages=259–269 |doi=10.2533/chimia.1997.259 |s2cid=100485418 |doi-access=free }}</ref>


Initially the company produced electricity. The following year, [[calcium carbide]] manufacture began using the electricity to heat a furnace to the 2000&nbsp;°C required for [[quicklime]] to react with coal. Lonza moved to neighbouring [[Visp]] (where it retains a production site today) in 1909. Competition from electric lighting reduced demand for calcium carbide and in 1915 Lonza started industrial production of [[calcium cyanamide]] which became popular as a cheap nitrogenous [[fertilizer|fertiliser]]s, only to be supplanted by urea. Several new processes were launched in the 1920s. In addition to an [[electrolysis]] plant capable of making 5800 m<sup>3</sup> hydrogen per hour, came metaldehyde, ammonia and ketene. In 1923, Lonza started to convert calcium carbide to [[metaldehyde]] (sold as a solid fuel under the brand 'Meta' and then slug repellant) via acetylene and acetaldehyde. In 1925, [[ammonia]] production was started, with a process licensed from Casale. Ammonia was also converted to [[nitric acid]]. With calcium cyanamide and [[calcium nitrate]] (made from nitric acid), Lonza commercialised formulated fertilisers starting in the 1930s. At the start of WWII, Lonza was contracted by the Swiss government to produce synthetic fuel, which it did by converting acetaldehyde to [[paraldehyde]], used as an additive in transport fuel. In 1928, [[ketene]] production started using acetic acid made by oxidation of acetaldehyde. Ketene was initially used to make [[cellulose acetate]] for [[rayon]] manufacture, but after 1947 Lonza converted most of its ketene to [[diketene]], which was then converted to a range of chemical precursors. Diketene capacity rose to 18'000t per year in 1993. In 1956, the production of [[niacin]] (an important [[vitamin]]) via 5-ethyl-2-methyl-pyridine. In the 1940s, Lonza used its C2 basis to enter the [[vinyl chloride]] business. The production was relocated to [[Sins, Aargau|Sins]] and finally discontinued.
Initially, the company produced electricity. The following year, [[calcium carbide]] manufacture began using the electricity to heat a furnace to the 2000&nbsp;°C required for [[quicklime]] to react with coal. Lonza moved to neighbouring [[Visp]] (where it retains a production site today) in 1909. Competition from electric lighting reduced demand for calcium carbide and in 1915 Lonza started industrial production of [[calcium cyanamide]] which became popular as a cheap nitrogenous [[fertilizer|fertilisers]], only to be supplanted by urea. Several new processes were launched in the 1920s. In addition to an [[electrolysis]] plant capable of making 5800 m<sup>3</sup> hydrogen per hour, came metaldehyde, ammonia and ketene. In 1923, Lonza started to convert calcium carbide to [[metaldehyde]] (sold as a solid fuel under the brand 'Meta' and then slug repellant) via acetylene and acetaldehyde. In 1925, [[ammonia]] production was started, with a process licensed from Casale. Ammonia was also converted to [[nitric acid]]. With calcium cyanamide and [[calcium nitrate]] (made from nitric acid), Lonza commercialised formulated fertilisers starting in the 1930s. At the start of [[World War II]], Lonza was contracted by the Swiss government to produce synthetic fuel, which it did by converting acetaldehyde to [[paraldehyde]], used as an additive in transport fuel. In 1928, [[ketene]] production started using acetic acid made by oxidation of acetaldehyde. Ketene was initially used to make [[cellulose acetate]] for [[rayon]] manufacture, but after 1947 Lonza converted most of its ketene to [[diketene]], which was then converted to a range of chemical precursors. Diketene capacity rose to 18'000t per year in 1993. In 1956, the production of [[Niacin (nutrient)|niacin]] (an important [[vitamin]]) via 5-ethyl-2-methyl-pyridine. In the 1940s, Lonza used its C2 basis to enter the [[vinyl chloride]] business. The production was relocated to [[Sins, Aargau|Sins]] and finally discontinued.


At the 1959 AGM, it was decided to back integrate into petrochemistry, and [[Montecatini (company)|Montecatini]] was contracted to build the world's smallest [[Cracking (chemistry)|cracker]] in Visp. The initial failure of this plant to meet its specifications triggered a CHF12mio penalty which Lonza used to build a research center.
At the 1959 AGM, it was decided to back integrate into petrochemistry, and [[Montecatini (company)|Montecatini]] was contracted to build the world's smallest [[Cracking (chemistry)|cracker]] in Visp. The initial failure of this plant to meet its specifications triggered a CHF12mio penalty, which Lonza used to build a research center.


*1962: Lonza acquired the Ftalital works in [[Scanzorosciate]], Italy which manufactured intermediates for polyester resins, and started work on
*1962: Lonza acquired the Ftalital works in [[Scanzorosciate]], Italy which manufactured intermediates for polyester resins, and started work on the new headquarters building in Basel.
*1969 Lonza expands into the United States and founds Lonza Inc. in [[Fair Lawn, New Jersey]]. This and the acquisition of a [[Mapleton, Illinois]] plant producing sorbitol, tertiary amines and quaternary ammonium compounds creates the Chemical Specialties Business Unit.
the new headquarters building in Basel.

*1969 Lonza expands into the United States and founds Lonza Inc. in [[Fair Lawn, NJ]]. This and the acquisition of a [[Mapleton, IL]] plant producing sorbitol, tertiary amines and quaternary ammonium compounds creates the Chemical Specialties Business Unit.
*1974, the group merged with aluminium firm [[Alusuisse]], after which the group moved into the biotechnology sector.
*1974, the group merged with aluminium firm [[Alusuisse]], after which the group moved into the biotechnology sector.
*1977: Lonza's first US fine chemicals plant starts operation in Bayport, TX
*1977: Lonza's first US fine chemicals plant starts operation in [[Bayport, Texas]]
*1980: Lonza's Polymers and Additives Business Unit starts with HQ in Milan, and the acquisition of a plasticizers and unsaturated polyester resins plant in [[San Giovanni Valdarno]] site.
*1980: Lonza's Polymers and Additives Business Unit starts with HQ in Milan, and the acquisition of a plasticizers and unsaturated polyester resins plant in [[San Giovanni Valdarno]] site.
*1984: Startup of the first multi-purpose plants at the fine chemicals complex in Visp, Switzerland, marking the inception of Lonza's contract manufacturing business.
*1984: Startup of the first multipurpose plants at the fine chemicals complex in Visp, Switzerland, marking the inception of Lonza's contract manufacturing business.
*1985: Acquisition of Molding Compounds SpA ([[Brembate]] Sopra, Italy) a company producing [[Sheet Moulding Compound]] and [[Bulk Moulding Compound]].
*1985: Acquisition of Molding Compounds SpA ([[Brembate]] Sopra, Italy) a company producing [[Sheet Moulding Compound]] and [[Bulk Moulding Compound]].
*1990: Acquisition Reglar Srl (Scanzorosciate, Italy) another SMC and BMC producer and Resinmec SpA, [[Pontirolo Nuovo]] and [[Pandino]], Italy, a thermoplastic resin compounder.
*1990: Acquisition Reglar Srl (Scanzorosciate, Italy) another SMC and BMC producer and Resinmec SpA, [[Pontirolo Nuovo]] and [[Pandino]], Italy, a thermoplastic resin compounder.
*1991: Purchase of Duroform GmbH in [[Miehlen]], Germany, another SMC and BMC producer, later incorporated into Polynt.
*1991: Purchase of Duroform GmbH in [[Miehlen]], Germany, another SMC and BMC producer, later incorporated into Polynt.
*1992: Acquisition of Biotec sro, ([[Kourim]], Czech Republic) a biotech producer of fine chemicals.
*1992: Acquisition of Biotec sro, ([[Kourim]], Czech Republic) a biotech producer of fine chemicals.
*1996: joint venture 80:20 with Singapore economic development board signed for a $125mio, 70kt/y [[isophthalic acid]] plant on Palau Sakra.<ref>{{cite web |title=Lonza expands into Singapore |url=https://www.icis.com/explore/resources/news/1996/01/12/3858/lonza-expands-into-singapore |website=icis.com |publisher=Independent Commodity Intelligence Services |access-date=8 October 2020 |date=12 Jan 1996}}</ref>
*1996: joint venture 80:20 with the [[Economic Development Board]] signed for a $125mio, 70kt/y [[isophthalic acid]] plant on Palau Sakra.<ref>{{cite web |title=Lonza expands into Singapore |url=https://www.icis.com/explore/resources/news/1996/01/12/3858/lonza-expands-into-singapore |website=icis.com |publisher=Independent Commodity Intelligence Services |access-date=8 October 2020 |date=12 Jan 1996}}</ref>
*1996: acquired [[Celltech]] Biologics and began producing mammalian cell cultures and monoclonal antibodies.
*1996: acquired [[Celltech]] Biologics and began producing mammalian cell cultures and monoclonal antibodies.
*1999 Lonza de-merged from the Alusuisse-Lonza Group and listed on the [[SWX Swiss Exchange]].<ref>{{Cite web|title=Lonza Group Ltd.|url=https://www.encyclopedia.com/books/politics-and-business-magazines/lonza-group-ltd|access-date=21 September 2020|website=Encyclopedia}}</ref>
*1999 Lonza de-merged from the Alusuisse-Lonza Group and listed on the [[SIX Swiss Exchange|SWX Swiss Exchange]].<ref>{{Cite web|title=Lonza Group Ltd.|url=https://www.encyclopedia.com/books/politics-and-business-magazines/lonza-group-ltd|access-date=21 September 2020|website=Encyclopedia}}</ref>
*2005 Lonza Poland Sp. Zoo launched with construction of a new site in [[Niepolomice]] (Poland) for the production of compounds and unsaturated polyester resins.<ref>{{cite web |title=2005: Niepolomice site |url=https://www.polynt.com/en/chemical-intermediates-company/history/ |publisher=Polynt Group |access-date=9 October 2020}}</ref>
*2005 Lonza Poland Sp. Zoo launched with construction of a new site in [[Niepołomice]] (Poland) for the production of compounds and unsaturated polyester resins.<ref>{{cite web |title=2005: Niepolomice site |url=https://www.polynt.com/en/chemical-intermediates-company/history/ |publisher=Polynt Group |access-date=9 October 2020}}</ref>
*2006,1Aug: Lonza S.p.A. changed its name to Polynt S.p.A., listed on the STAR segment of the [[Italian Bourse|Italian Stock Exchange]], on 30 October.<ref>{{cite web |title=2006: Polynt S.p.A. |url=https://www.polynt.com/en/chemical-intermediates-company/history/ |publisher=Polynt Group |access-date=9 October 2020}}</ref> This marked the exit of Lonza from the resins business. In 2020, Polynt is held by private equity.
*2006,1Aug: Lonza S.p.A. changed its name to Polynt S.p.A., listed on the STAR segment of the [[Borsa Italiana|Italian Stock Exchange]], on 30 October.<ref>{{cite web |title=2006: Polynt S.p.A. |url=https://www.polynt.com/en/chemical-intermediates-company/history/ |publisher=Polynt Group |access-date=9 October 2020}}</ref> This marked the exit of Lonza from the resins business. In 2020, Polynt is held by private equity.
*2007: Lonza Singapore Pte Ltd. (the owner of the isophthalic acid plant) sold to [[Perstorp Group]] (already, and still in 2020, under control of private equity group [[PAI Partners]]) for USD 138 million<ref>{{cite web |title=Lonza sells Singapore PIA plant to Perstorp |url=https://www.gupta-verlag.com/news/industry/4202/lonza-sells-singapore-pia-plant-to-perstorp |publisher=Dr. Gupta Verlag |access-date=8 October 2020 |date=10 October 2007}}</ref>
*2007: Lonza Singapore Pte Ltd. (the owner of the isophthalic acid plant) sold to [[PAI Partners|Perstorp Group]] (already, and still in 2020, under control of private equity group [[PAI Partners]]) for USD 138 million<ref>{{cite web |title=Lonza sells Singapore PIA plant to Perstorp |url=https://www.gupta-verlag.com/news/industry/4202/lonza-sells-singapore-pia-plant-to-perstorp |publisher=Dr. Gupta Verlag |access-date=8 October 2020 |date=10 October 2007}}</ref>
* 2011 October: acquired American firm Arch Chemicals for $1.4 billion, thus becoming the world's largest manufacturer of [[biocide]]s.<ref>{{cite news|last=Simonian|first=Haig|title=Lonza in $1.4bn acquisition of Arch Chemicals|url=http://www.ft.com/cms/s/0/87235890-ab98-11e0-8a64-00144feabdc0.html#axzz1dakMfQnQ|access-date=13 November 2011|newspaper=[[Financial Times]]|date=11 July 2011}}</ref>
* 2011 October: acquired American firm Arch Chemicals for $1.4 billion, thus becoming the world's largest manufacturer of [[biocide]]s.<ref>{{cite news|last=Simonian|first=Haig|title=Lonza in $1.4bn acquisition of Arch Chemicals|url=http://www.ft.com/cms/s/0/87235890-ab98-11e0-8a64-00144feabdc0.html#axzz1dakMfQnQ|access-date=13 November 2011|newspaper=[[Financial Times]]|date=11 July 2011}}</ref>
*2016 August 15: announced $300mio acquisition of US based InterHealth Nutraceuticals,<ref>{{Cite press release|title=Lonza Extends Its Reach in the Healthcare Continuum with Acquisition of InterHealth Nutraceuticals|date=15 August 2016|publisher=Lonza|url=https://www.lonza.com/about-lonza/media-center/news/Tensid/2016-08-15-05-00-English.aspx|access-date=2018-04-15}}{{Self-published source|date=September 2018}}</ref> a leader in research, development, manufacture and marketing of value-added nutritional ingredients for use in dietary supplements.
*2016 August 15: announced $300mio acquisition of US based InterHealth Nutraceuticals,<ref>{{Cite press release|title=Lonza Extends Its Reach in the Healthcare Continuum with Acquisition of InterHealth Nutraceuticals|date=15 August 2016|publisher=Lonza|url=https://www.lonza.com/about-lonza/media-center/news/Tensid/2016-08-15-05-00-English.aspx|access-date=2018-04-15}}{{Self-published source|date=September 2018}}</ref> a leader in research, development, manufacture and marketing of value-added nutritional ingredients for use in dietary supplements.
*2016 December : announced acquisition of [[Capsugel]] for {{US$|5.5 billion}} from private equity firm [[Kohlberg Kravis Roberts|KKR]].<ref>{{Cite news|url=https://www.genengnews.com/gen-news-highlights/lonza-buys-capsugel-for-55b-cash/81253556|title=Lonza Buys Capsugel for $5.5B Cash|last=<!--no byline-->|date=15 December 2016|work=Genetic Engineering & Biotechnology News|access-date=2018-04-15}}</ref>
*2016 December : announced acquisition of [[Capsugel]] for {{US$|5.5 billion}} from private equity firm [[Kohlberg Kravis Roberts|KKR]].<ref>{{Cite news|url=https://www.genengnews.com/gen-news-highlights/lonza-buys-capsugel-for-55b-cash/81253556|title=Lonza Buys Capsugel for $5.5B Cash|last=<!--no byline-->|date=15 December 2016|work=Genetic Engineering & Biotechnology News|access-date=2018-04-15}}</ref>
*2017 February, announced construction of a CHF 290 million biopharmaceuticals plant (with the French pharmaceutical company [[Sanofi]]) in Visp. The<ref>[https://telebasel.ch/2017/02/27/lonza-und-sanofi-bauen-gemeinsame-fabrik-im-wallis/ Lonza und Sanofi bauen gemeinsame Fabrik im Wallis]. Telebasel, February 27, 2017</ref>
*2017 February, announced construction of a CHF 290 million biopharmaceuticals plant (with the French pharmaceutical company [[Sanofi]]) in Visp.<ref>[https://telebasel.ch/2017/02/27/lonza-und-sanofi-bauen-gemeinsame-fabrik-im-wallis/ Lonza und Sanofi bauen gemeinsame Fabrik im Wallis]. Telebasel, February 27, 2017</ref>
*2021 July, Lonza Specialty Ingredients divested to Bain and Cinven for CHF 4.2 billion.<ref>{{Cite web |date= |title=AR2021 |url=https://www.lonza.com/investor-relations/-/media/F40C2A0B78E74B328C640C8750272F94.ashx |access-date= |website=Lonza.com}}</ref>
*2024 March, acquisition of [[Genentech]]'s [[Vacaville, California]] site from [[Roche]] for $1.2 billion.<ref>{{Cite web |date=2024-03-20 |title=Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn - Pharmafile |url=https://pharmafile.com/news/lonza-to-acquire-biologics-site-in-vacaville-us-from-roche-for-1-2bn/ |access-date=2024-03-20 |website=pharmafile.com |language=en-GB}}</ref>


Lonza is involved in the manufacturing of [[biologics]] with several pharmaceutical companies. Lonza entered into a partnership with [[Teva Pharmaceutical Industries|Teva]] in 2009 to develop and manufacture biosimilars. In 2010, they made a deal with [[GlaxoSmithKline]] to manufacture therapeutic [[monoclonal antibodies]]. In 2014, Lonza entered into an agreement with [[Bristol-Myers Squibb]] to manufacture two biologic drugs. Lonza also manufactures [[Imbruvica]] for [[Pharmacyclics]] and [[Mydicar]] for [[Celladon]]. In 2015, Lonza contracted with [[Alexion]] to construct a new facility dedicated to Alexion manufacturing. In 2017, Lonza and [[Sanofi]] partnered to construct a new facility for production of biologics.<ref>{{Cite web|url=https://www.lonza.com/about-lonza/company-profile/company-history.aspx|title=Company History|last=<!--no byline-->|date=<!--no source date; copyright 2018-->|website=Company Profile|access-date=2018-04-15}}{{Self-published source|date=September 2018}}</ref>
Lonza is involved in the manufacturing of [[biologics]] with several pharmaceutical companies. Lonza entered into a partnership with [[Teva Pharmaceutical Industries|Teva]] in 2009 to develop and manufacture biosimilars. In 2010, they made a deal with [[GSK plc|GlaxoSmithKline]] to manufacture therapeutic [[monoclonal antibodies]]. In 2014, Lonza entered into an agreement with [[Bristol-Myers Squibb]] to manufacture two biologic drugs. Lonza also manufactures [[Imbruvica]] for [[Pharmacyclics]] and [[Mydicar]] for [[Celladon]]. In 2015, Lonza contracted with [[Alexion Pharmaceuticals|Alexion]] to construct a new facility dedicated to Alexion manufacturing. In 2017, Lonza and [[Sanofi]] partnered to construct a new facility for production of biologics.<ref>{{Cite web|url=https://www.lonza.com/about-lonza/company-profile/company-history.aspx|title=Company History|last=<!--no byline-->|date=<!--no source date; copyright 2018-->|website=Company Profile|access-date=2018-04-15}}{{Self-published source|date=September 2018}}</ref>


In May 2020, [[Moderna]] struck a manufacturing deal with Lonza to produce its (mRNA-1273) [[COVID-19 vaccine]] active ingredient while expanding sterile production and fill-finish activities to 500 million doses starting in 2021.<ref>Taylor, N. (Aug. 2020). [https://WWW.BIOPHARMA-REPORTER.COM/ARTICLE/2020/08/25/MODERNA-SCALING-UP-EX-US-COVID-19-VACCINE-CAPACITY-AS-EU-DEAL-NEARS Moderna scaling up ex-US COVID-19 vaccine capacity as EU deal nears]. ''BioPharma-Reporter.com''. Retrieved 23 September 2020.</ref> Production of the mRNA bulk vaccine started in January 2021, soon after an official visit by [[Federal Council (Switzerland)|Swiss Federal Councilor]] [[Alain Berset]]. Lonza Group is responsible for the global production of two-thirds of the raw materials for the Moderna vaccine at combined U.S. and Swiss facilities. The company also started to collaborate with Altimmune Inc. for the development of a [[Nasal vaccine|nasal COVID-19 vaccine]].<ref>[https://www.reuters.com/article/us-health-coronavirus-lonza-moderna/lonza-plant-in-switzerland-starts-making-ingredients-for-moderna-covid-shot-idUSKBN29G26L "Lonza plant in Switzerland starts making ingredients for Moderna COVID shot"]. ''Reuters''. Retrieved 15 March 2021.</ref><ref>[https://www.tdg.ch/lonza-collabore-avec-altimmune-pour-developper-son-vaccin-nasal-998684679639 "Lonza collabore avec Altimmune pour développer son vaccin nasal"](in french). ''Tribune de Genève''. Retrieved 15 March 2021.</ref>
In May 2020, [[Moderna]] struck a manufacturing deal with Lonza to produce its (mRNA-1273) [[COVID-19 vaccine]] active ingredient while expanding sterile production and fill-finish activities to 500 million doses starting in 2021.<ref>Taylor, N. (Aug. 2020). [https://WWW.BIOPHARMA-REPORTER.COM/ARTICLE/2020/08/25/MODERNA-SCALING-UP-EX-US-COVID-19-VACCINE-CAPACITY-AS-EU-DEAL-NEARS Moderna scaling up ex-US COVID-19 vaccine capacity as EU deal nears]. ''BioPharma-Reporter.com''. Retrieved 23 September 2020.</ref> Production of the mRNA bulk vaccine started in January 2021, soon after an official visit by [[Federal Council (Switzerland)|Swiss Federal Councilor]] [[Alain Berset]]. Lonza Group was responsible for the global production of two-thirds of the raw materials for the Moderna vaccine at combined U.S. and Swiss facilities.


== Corporate structure ==
== Corporate structure ==
As of 2020, Lonza's business areas include:
As of 2024, Lonza's business areas include:


* Biologics: mammalian, microbial, licensing, bioconjugates, parenteral drug product services, mRNA
* Lonza Life Science Ingredients (LSI): Food and feed additives for health promotion through to complex chemical intermediates for agriculture.
* Small Molecules: active pharmaceutical ingredients, drug product formulation
* Lonza Microbial Control (LMC): Chemicals to control or selectively inhibit the growth of microorganisms. The LMC division produces the biocides DMDM-hydantoin, iodocarb, benzisothiazolinone (BIT), methylisothiazolinone (MIT) and chloromethylisothiazolinone (CMIT).
* Cell & Gene: cell and gene technologies, personalized medicine, bioscience
* Lonza Custom Manufacturing (LCM): Manufacture of ingredients that are used in major medicines for the treatment of patients with cardiovascular diseases, cancer, neurological diseases and infectious diseases.
* Capsules & Health Ingredients: capsules, health ingredients
* Lonza Bioscience (LBS): Manufacture of tools used by life science customers to research, develop, manufacture, and test therapeutic products.


In November 2019, [[Chairman]] Albert Baehny became both chairman and interim [[CEO]] of Lonza after [[chief executive officer]] (CEO) Marc Funk left after 9 months.<ref>{{Cite web|url=https://www.fiercepharma.com/manufacturing/lonza-leader-marc-funk-quits-after-just-nine-months-as-ceo|title=Lonza leader Marc Funk quits after just 9 months as CEO|website=FiercePharma}}</ref>
In November 2019, [[Chairman]] Albert Baehny became both chairman and interim [[CEO]] of Lonza after [[chief executive officer]] (CEO) Marc Funk left after 9 months.<ref>{{Cite web|url=https://www.fiercepharma.com/manufacturing/lonza-leader-marc-funk-quits-after-just-nine-months-as-ceo|title=Lonza leader Marc Funk quits after just 9 months as CEO|website=FiercePharma}}</ref> In November 2020, Pierre-Alain Ruffieux commenced his role as Chief Executive Officer<ref>{{Cite web |title=Lonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux |url=https://www.lonza.com/news/2020-11-02-06-00 |website=Lonza.com}}</ref> which ended at the end of September 2023, totaling 2 years and 11 months in the position of CEO. [[Chairman]] Albert Baehny became again, both chairman and interim [[CEO]], as from October 2023.<ref>{{Cite news |date=18 September 2023 |title=Ad Hoc announcement pursuant to Art. 53 LR |url=https://www.lonza.com/news/2023-09-18-07-00 |access-date=20 September 2023}}</ref>

In May 2024, Jean-Marc Huët was elected Chairman following the retirement of Albert Baehny, who had held the position of Chairman and interim CEO.<ref>{{Cite news |last=Feldges |first=Dominic |date=5 June 2024 |title=Auch Historiker können Topmanager werden: Jean-Marc Huët schafft es erst bei Heineken und nun bei Lonza ins Präsidium |url=https://www.nzz.ch/wirtschaft/jean-marc-huet-praesident-von-heineken-und-nun-auch-von-lonza-ld.1833041 |url-status= |work=[[Neue Zürcher Zeitung]]}}</ref> In July 2024, Wolfgang Wienand commenced his role as CEO of Lonza.<ref>{{Cite news |last=Hotz |first=Michael |date=2 April 2024 |title=Neuer Lonza-Chef: Vom Fechtprofi an die Spitze |url=https://www.handelszeitung.ch/unternehmen/vom-fechtprofi-an-die-spitze-698636 |work=[[Handelszeitung]]}}</ref>


== Business operations ==
== Business operations ==
{{As of|2023}}, Lonza had over thirty development and manufacturing sites located in countries including Switzerland, the United States, the United Kingdom, Belgium, Spain, France, Mexico, Brazil, Japan, India, China and Singapore.<ref name=":0">{{Cite web|url=https://www.lonza.com/about-lonza/company-profile/facts-and-figures/facts.aspx|title=Fact Sheet|last=<!--no byline-->|date=<!--no source date; copyright 2018-->|website=Company Profile|publisher=Lonza|access-date=2018-04-15}}{{Self-published source|date=September 2018}}</ref>
{{As of|2018}}, Lonza had twenty-four self-described major sites located in the United States, India, the Czech Republic, Belgium, Spain, China, France, South Africa, Switzerland, Singapore, Mexico, Japan, Brazil and the United Kingdom.<ref name=":0">{{Cite web|url=https://www.lonza.com/about-lonza/company-profile/facts-and-figures/facts.aspx|title=Fact Sheet|last=<!--no byline-->|date=<!--no source date; copyright 2018-->|website=Company Profile|publisher=Lonza|access-date=2018-04-15}}{{Self-published source|date=September 2018}}</ref> This site accounting shows significant changes from a 2016 self-description, which listed sixteen major sites.<ref>{{Cite web|url=https://www.lonza.com/about-lonza/company-profile/facts-and-figures/facts.aspx|title=Facts|last=<!--no byline-->|date=<!--no source date; copyright 2016-->|website=Company Profile|publisher=Lonza|archive-url=https://web.archive.org/web/20161010200646/https://www.lonza.com/about-lonza/company-profile/facts-and-figures/facts.aspx|archive-date=10 October 2016|url-status=<!--this is a historical version of the page-->|access-date=2018-04-15}}{{Self-published source|date=September 2018}}</ref> The presence in India was established in [[Genome Valley]], where ground was broken in 2011.<ref name=":1">{{Cite news|url=http://www.business-standard.com/article/companies/lonza-to-invest-rs-250-cr-in-genome-valley-110092500077_1.html|title=Lonza to invest Rs 250 cr in Genome Valley|last=<!--byline is "BS Reporter"-->|date=25 September 2010<!-- last update 20 January 2013 -->|work=Business Standard|access-date=2018-04-15|location=India}}</ref><ref>{{Cite web|url=http://pharma.industry-focus.net/bio-pharmaceuticals/179-lonza-group-to-set-up-a-bio-pharma-unit-at-genome-valley-lonza-group-to-set-up-a-bio-pharma-unit-at-genome-valley.html|title=Lonza Group to set up a bio pharma unit at Genome Valley|last=<!--no byline-->|date=<!--not specified-->|publisher=ibis|access-date=2018-04-15}}</ref><ref>{{Cite press release|title=Lonza provisionally allotted 30 Acres of land in the "Genome Valley", Hyderabad (India)|date=29 May 2009|publisher=Lonza|url=https://www.lonza.com/about-lonza/media-center/news/2009/allotment-30-acres-of-land-in-the-genome-valley.aspx}}{{Self-published source|date=September 2018}}</ref>


In 2018, Lonza opened a {{Convert|300,000|sqft|m2}} facility in the United States in [[Pearland, Texas]] (a suburb of Houston).<ref name=":2">{{Cite news|url=https://www.genengnews.com/gen-news-highlights/lonza-opens-cell-and-gene-therapy-facility-in-pearland-tx/81255682/|title=Lonza Opens Cell and Gene Therapy Facility in Pearland, TX|last=Philippidis|first=Alex|date=10 April 2018|work=Genetic Engineering & Biotechnology News|access-date=2018-04-15|department=GEN News Highlights}}</ref> This is one of four sites which are focused on cell and gene therapy, the other three being in [[Portsmouth, New Hampshire]]; [[Geleen|Geleen, Netherlands]]; and Singapore.<ref name=":2" />
This site accounting shows significant changes from a 2016 self-description, which listed sixteen major sites.<ref>{{Cite web|url=https://www.lonza.com/about-lonza/company-profile/facts-and-figures/facts.aspx|title=Facts|last=<!--no byline-->|date=<!--no source date; copyright 2016-->|website=Company Profile|publisher=Lonza|archive-url=https://web.archive.org/web/20161010200646/https://www.lonza.com/about-lonza/company-profile/facts-and-figures/facts.aspx|archive-date=10 October 2016|url-status=<!--this is a historical version of the page-->|access-date=2018-04-15}}{{Self-published source|date=September 2018}}</ref> The presence in India was established in [[Genome Valley]], where ground was broken in 2011.<ref name=":1">{{Cite news|url=http://www.business-standard.com/article/companies/lonza-to-invest-rs-250-cr-in-genome-valley-110092500077_1.html|title=Lonza to invest Rs 250 cr in Genome Valley|last=<!--byline is "BS Reporter"-->|date=25 September 2010<!-- last update 20 January 2013 -->|work=Business Standard|access-date=2018-04-15|location=India}}</ref><ref>{{Cite web|url=http://pharma.industry-focus.net/bio-pharmaceuticals/179-lonza-group-to-set-up-a-bio-pharma-unit-at-genome-valley-lonza-group-to-set-up-a-bio-pharma-unit-at-genome-valley.html|title=Lonza Group to set up a bio pharma unit at Genome Valley|last=<!--no byline-->|date=<!--not specified-->|publisher=ibis|access-date=2018-04-15}}</ref><ref>{{Cite press release|title=Lonza provisionally allotted 30 Acres of land in the "Genome Valley", Hyderabad (India)|date=29 May 2009|publisher=Lonza|url=https://www.lonza.com/about-lonza/media-center/news/2009/allotment-30-acres-of-land-in-the-genome-valley.aspx}}{{Self-published source|date=September 2018}}</ref> In 2018, Lonza opened a {{Convert|300,000|sqft|m2}} facility in the United States in [[Pearland, Texas]] (a suburb of Houston).<ref name=":2">{{Cite news|url=https://www.genengnews.com/gen-news-highlights/lonza-opens-cell-and-gene-therapy-facility-in-pearland-tx/81255682/|title=Lonza Opens Cell and Gene Therapy Facility in Pearland, TX|last=Philippidis|first=Alex|date=10 April 2018|work=Genetic Engineering & Biotechnology News|access-date=2018-04-15|department=GEN News Highlights}}</ref> This is one of four sites which are focused on cell and gene therapy, the other three being in [[Portsmouth, New Hampshire]]; [[Geleen|Geleen, Netherlands]]; and Singapore.<ref name=":2" /> In October 2024, the company completed the acquisition of the [[Genentech]] biologics manufacturing site in [[Vacaville, California]], from Roche.


{{As of|2020}}, the company has employed over 15,000 people,<ref name=":3" />{{Rp|22}} across about 35 countries.<ref name=":3">{{Cite web|url=https://www.lonza.com/~/media/Files/Investor%20Relations/Financial%20Reports/2016_Lonza_Annual_Report_Export_v2.ashx?la=en|title=Annual Report 2016|last=<!--no byline-->|date=<!--not specified-->|website=Investor Relations|publisher=Lonza|format=PDF|access-date=2018-04-15}}{{Self-published source|date=September 2018}}</ref>{{Rp|89}} {{As of|2018|alt=By 2018,}} employment was noted as 14,500 across 120 sites.<ref name=":2" />
{{As of|2023}}, the company employed approximately 18,000 people across more than 30 locations.<ref>{{Cite web |url=https://www.lonza.com/about-us |title=About Us |publisher=Lonza |access-date=February 6, 2023}}</ref><ref>{{Cite web |url=https://www.macroaxis.com/invest/ratio/LZAGY/Number-of-Employees |title=Lonza Number of Employees |publisher=Macroaxis |access-date=February 6, 2023}}</ref>


==References==
==References==
Line 90: Line 90:
{{Authority control}}
{{Authority control}}


[[Category:Biotechnology companies of Switzerland]]
[[Category:Companies listed on the SIX Swiss Exchange]]
[[Category:Companies listed on the Singapore Exchange]]
[[Category:Dual-listed companies]]
[[Category:Manufacturing companies based in Basel]]
[[Category:Manufacturing companies based in Basel]]
[[Category:Manufacturing companies established in 1897]]
[[Category:Manufacturing companies established in 1897]]
[[Category:Biotechnology companies of Switzerland]]
[[Category:Swiss brands]]
[[Category:Multinational companies headquartered in Switzerland]]
[[Category:Multinational companies headquartered in Switzerland]]
[[Category:Chemical companies established in 1897]]
[[Category:Pharmaceutical companies established in 1897]]
[[Category:Pharmaceutical companies established in 1897]]
[[Category:Companies listed on the SIX Swiss Exchange]]
[[Category:1897 establishments in Switzerland]]
[[Category:Companies in the Swiss Market Index]]

Latest revision as of 08:05, 3 December 2024

Lonza Group AG
Company typeAktiengesellschaft
ISINCH0013841017 Edit this on Wikidata
Industry
Founded1897; 127 years ago (1897)
HeadquartersBasel, Switzerland
Key people
ProductsBiopharmaceuticals
RevenueIncrease CHF 6.72 billion (2023)[1]
Decrease CHF 880 million (2023)[1]
Decrease CHF 655 million (2023)[1]
Total assetsDecrease CHF 16.8 billion (2023)[1]
Total equityDecrease CHF 9.51 billion (2023)[1]
Number of employees
18,000 (2023)[1]
Websitelonza.com

Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.

History

[edit]

Lonza was founded in 1897 in the small Swiss town of Gampel, situated in the canton of Valais, taking its name from the nearby river. In the course of the 20th century Lonza evolved from hydroelectricity and C2 chemistry, through nitrogen chemistry to petrochemistry before moving into fine chemistry and biochemistry.[2]

Initially, the company produced electricity. The following year, calcium carbide manufacture began using the electricity to heat a furnace to the 2000 °C required for quicklime to react with coal. Lonza moved to neighbouring Visp (where it retains a production site today) in 1909. Competition from electric lighting reduced demand for calcium carbide and in 1915 Lonza started industrial production of calcium cyanamide which became popular as a cheap nitrogenous fertilisers, only to be supplanted by urea. Several new processes were launched in the 1920s. In addition to an electrolysis plant capable of making 5800 m3 hydrogen per hour, came metaldehyde, ammonia and ketene. In 1923, Lonza started to convert calcium carbide to metaldehyde (sold as a solid fuel under the brand 'Meta' and then slug repellant) via acetylene and acetaldehyde. In 1925, ammonia production was started, with a process licensed from Casale. Ammonia was also converted to nitric acid. With calcium cyanamide and calcium nitrate (made from nitric acid), Lonza commercialised formulated fertilisers starting in the 1930s. At the start of World War II, Lonza was contracted by the Swiss government to produce synthetic fuel, which it did by converting acetaldehyde to paraldehyde, used as an additive in transport fuel. In 1928, ketene production started using acetic acid made by oxidation of acetaldehyde. Ketene was initially used to make cellulose acetate for rayon manufacture, but after 1947 Lonza converted most of its ketene to diketene, which was then converted to a range of chemical precursors. Diketene capacity rose to 18'000t per year in 1993. In 1956, the production of niacin (an important vitamin) via 5-ethyl-2-methyl-pyridine. In the 1940s, Lonza used its C2 basis to enter the vinyl chloride business. The production was relocated to Sins and finally discontinued.

At the 1959 AGM, it was decided to back integrate into petrochemistry, and Montecatini was contracted to build the world's smallest cracker in Visp. The initial failure of this plant to meet its specifications triggered a CHF12mio penalty, which Lonza used to build a research center.

  • 1962: Lonza acquired the Ftalital works in Scanzorosciate, Italy which manufactured intermediates for polyester resins, and started work on the new headquarters building in Basel.
  • 1969 Lonza expands into the United States and founds Lonza Inc. in Fair Lawn, New Jersey. This and the acquisition of a Mapleton, Illinois plant producing sorbitol, tertiary amines and quaternary ammonium compounds creates the Chemical Specialties Business Unit.
  • 1974, the group merged with aluminium firm Alusuisse, after which the group moved into the biotechnology sector.
  • 1977: Lonza's first US fine chemicals plant starts operation in Bayport, Texas
  • 1980: Lonza's Polymers and Additives Business Unit starts with HQ in Milan, and the acquisition of a plasticizers and unsaturated polyester resins plant in San Giovanni Valdarno site.
  • 1984: Startup of the first multipurpose plants at the fine chemicals complex in Visp, Switzerland, marking the inception of Lonza's contract manufacturing business.
  • 1985: Acquisition of Molding Compounds SpA (Brembate Sopra, Italy) a company producing Sheet Moulding Compound and Bulk Moulding Compound.
  • 1990: Acquisition Reglar Srl (Scanzorosciate, Italy) another SMC and BMC producer and Resinmec SpA, Pontirolo Nuovo and Pandino, Italy, a thermoplastic resin compounder.
  • 1991: Purchase of Duroform GmbH in Miehlen, Germany, another SMC and BMC producer, later incorporated into Polynt.
  • 1992: Acquisition of Biotec sro, (Kourim, Czech Republic) a biotech producer of fine chemicals.
  • 1996: joint venture 80:20 with the Economic Development Board signed for a $125mio, 70kt/y isophthalic acid plant on Palau Sakra.[3]
  • 1996: acquired Celltech Biologics and began producing mammalian cell cultures and monoclonal antibodies.
  • 1999 Lonza de-merged from the Alusuisse-Lonza Group and listed on the SWX Swiss Exchange.[4]
  • 2005 Lonza Poland Sp. Zoo launched with construction of a new site in Niepołomice (Poland) for the production of compounds and unsaturated polyester resins.[5]
  • 2006,1Aug: Lonza S.p.A. changed its name to Polynt S.p.A., listed on the STAR segment of the Italian Stock Exchange, on 30 October.[6] This marked the exit of Lonza from the resins business. In 2020, Polynt is held by private equity.
  • 2007: Lonza Singapore Pte Ltd. (the owner of the isophthalic acid plant) sold to Perstorp Group (already, and still in 2020, under control of private equity group PAI Partners) for USD 138 million[7]
  • 2011 October: acquired American firm Arch Chemicals for $1.4 billion, thus becoming the world's largest manufacturer of biocides.[8]
  • 2016 August 15: announced $300mio acquisition of US based InterHealth Nutraceuticals,[9] a leader in research, development, manufacture and marketing of value-added nutritional ingredients for use in dietary supplements.
  • 2016 December : announced acquisition of Capsugel for US$5.5 billion from private equity firm KKR.[10]
  • 2017 February, announced construction of a CHF 290 million biopharmaceuticals plant (with the French pharmaceutical company Sanofi) in Visp.[11]
  • 2021 July, Lonza Specialty Ingredients divested to Bain and Cinven for CHF 4.2 billion.[12]
  • 2024 March, acquisition of Genentech's Vacaville, California site from Roche for $1.2 billion.[13]

Lonza is involved in the manufacturing of biologics with several pharmaceutical companies. Lonza entered into a partnership with Teva in 2009 to develop and manufacture biosimilars. In 2010, they made a deal with GlaxoSmithKline to manufacture therapeutic monoclonal antibodies. In 2014, Lonza entered into an agreement with Bristol-Myers Squibb to manufacture two biologic drugs. Lonza also manufactures Imbruvica for Pharmacyclics and Mydicar for Celladon. In 2015, Lonza contracted with Alexion to construct a new facility dedicated to Alexion manufacturing. In 2017, Lonza and Sanofi partnered to construct a new facility for production of biologics.[14]

In May 2020, Moderna struck a manufacturing deal with Lonza to produce its (mRNA-1273) COVID-19 vaccine active ingredient while expanding sterile production and fill-finish activities to 500 million doses starting in 2021.[15] Production of the mRNA bulk vaccine started in January 2021, soon after an official visit by Swiss Federal Councilor Alain Berset. Lonza Group was responsible for the global production of two-thirds of the raw materials for the Moderna vaccine at combined U.S. and Swiss facilities.

Corporate structure

[edit]

As of 2024, Lonza's business areas include:

  • Biologics: mammalian, microbial, licensing, bioconjugates, parenteral drug product services, mRNA
  • Small Molecules: active pharmaceutical ingredients, drug product formulation
  • Cell & Gene: cell and gene technologies, personalized medicine, bioscience
  • Capsules & Health Ingredients: capsules, health ingredients

In November 2019, Chairman Albert Baehny became both chairman and interim CEO of Lonza after chief executive officer (CEO) Marc Funk left after 9 months.[16] In November 2020, Pierre-Alain Ruffieux commenced his role as Chief Executive Officer[17] which ended at the end of September 2023, totaling 2 years and 11 months in the position of CEO. Chairman Albert Baehny became again, both chairman and interim CEO, as from October 2023.[18]

In May 2024, Jean-Marc Huët was elected Chairman following the retirement of Albert Baehny, who had held the position of Chairman and interim CEO.[19] In July 2024, Wolfgang Wienand commenced his role as CEO of Lonza.[20]

Business operations

[edit]

As of 2023, Lonza had over thirty development and manufacturing sites located in countries including Switzerland, the United States, the United Kingdom, Belgium, Spain, France, Mexico, Brazil, Japan, India, China and Singapore.[21]

This site accounting shows significant changes from a 2016 self-description, which listed sixteen major sites.[22] The presence in India was established in Genome Valley, where ground was broken in 2011.[23][24][25] In 2018, Lonza opened a 300,000 square feet (28,000 m2) facility in the United States in Pearland, Texas (a suburb of Houston).[26] This is one of four sites which are focused on cell and gene therapy, the other three being in Portsmouth, New Hampshire; Geleen, Netherlands; and Singapore.[26] In October 2024, the company completed the acquisition of the Genentech biologics manufacturing site in Vacaville, California, from Roche.

As of 2023, the company employed approximately 18,000 people across more than 30 locations.[27][28]

References

[edit]
  1. ^ a b c d e f "Annual Report 2023" (PDF). Lonza Group. Retrieved 10 June 2024.
  2. ^ Eschenmooser, Walter (June 1997). "100 Years of Progress with LONZA". CHIMIA. 51 (6): 259–269. doi:10.2533/chimia.1997.259. S2CID 100485418.
  3. ^ "Lonza expands into Singapore". icis.com. Independent Commodity Intelligence Services. 12 Jan 1996. Retrieved 8 October 2020.
  4. ^ "Lonza Group Ltd". Encyclopedia. Retrieved 21 September 2020.
  5. ^ "2005: Niepolomice site". Polynt Group. Retrieved 9 October 2020.
  6. ^ "2006: Polynt S.p.A." Polynt Group. Retrieved 9 October 2020.
  7. ^ "Lonza sells Singapore PIA plant to Perstorp". Dr. Gupta Verlag. 10 October 2007. Retrieved 8 October 2020.
  8. ^ Simonian, Haig (11 July 2011). "Lonza in $1.4bn acquisition of Arch Chemicals". Financial Times. Retrieved 13 November 2011.
  9. ^ "Lonza Extends Its Reach in the Healthcare Continuum with Acquisition of InterHealth Nutraceuticals" (Press release). Lonza. 15 August 2016. Retrieved 2018-04-15.[self-published source]
  10. ^ "Lonza Buys Capsugel for $5.5B Cash". Genetic Engineering & Biotechnology News. 15 December 2016. Retrieved 2018-04-15.
  11. ^ Lonza und Sanofi bauen gemeinsame Fabrik im Wallis. Telebasel, February 27, 2017
  12. ^ "AR2021". Lonza.com.
  13. ^ "Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn - Pharmafile". pharmafile.com. 2024-03-20. Retrieved 2024-03-20.
  14. ^ "Company History". Company Profile. Retrieved 2018-04-15.[self-published source]
  15. ^ Taylor, N. (Aug. 2020). Moderna scaling up ex-US COVID-19 vaccine capacity as EU deal nears. BioPharma-Reporter.com. Retrieved 23 September 2020.
  16. ^ "Lonza leader Marc Funk quits after just 9 months as CEO". FiercePharma.
  17. ^ "Lonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux". Lonza.com.
  18. ^ "Ad Hoc announcement pursuant to Art. 53 LR". 18 September 2023. Retrieved 20 September 2023.
  19. ^ Feldges, Dominic (5 June 2024). "Auch Historiker können Topmanager werden: Jean-Marc Huët schafft es erst bei Heineken und nun bei Lonza ins Präsidium". Neue Zürcher Zeitung.
  20. ^ Hotz, Michael (2 April 2024). "Neuer Lonza-Chef: Vom Fechtprofi an die Spitze". Handelszeitung.
  21. ^ "Fact Sheet". Company Profile. Lonza. Retrieved 2018-04-15.[self-published source]
  22. ^ "Facts". Company Profile. Lonza. Archived from the original on 10 October 2016. Retrieved 2018-04-15.[self-published source]
  23. ^ "Lonza to invest Rs 250 cr in Genome Valley". Business Standard. India. 25 September 2010. Retrieved 2018-04-15.
  24. ^ "Lonza Group to set up a bio pharma unit at Genome Valley". ibis. Retrieved 2018-04-15.
  25. ^ "Lonza provisionally allotted 30 Acres of land in the "Genome Valley", Hyderabad (India)" (Press release). Lonza. 29 May 2009.[self-published source]
  26. ^ a b Philippidis, Alex (10 April 2018). "Lonza Opens Cell and Gene Therapy Facility in Pearland, TX". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved 2018-04-15.
  27. ^ "About Us". Lonza. Retrieved February 6, 2023.
  28. ^ "Lonza Number of Employees". Macroaxis. Retrieved February 6, 2023.
[edit]

Media related to Lonza Group at Wikimedia Commons